Aila Gareayaghi | Post-traumatic Stress Disorder | Best Researcher Award

Dr. Aila Gareayaghi | Post-traumatic Stress Disorder | Best Researcher Award

Dr. Aila Gareayaghi is a committed psychiatrist based in Kocaeli, Türkiye, with a deep passion for trauma-focused therapy, online psychotherapy, and mood and anxiety disorders. She holds the position of Lecturer and Psychiatrist at Kocaeli University and serves as Chair of the Kocaeli Branch of the Psychiatric Association of Türkiye. Dr. Gareayaghi’s extensive clinical and academic work includes innovative research on telepsychiatry, particularly in post-disaster mental health following Türkiye’s 2023 Kahramanmaraş Earthquakes. Her international experience includes a clerkship at Johns Hopkins University, Maryland. Beyond her clinical practice, she is active in research, conference presentations, and has authored multiple peer-reviewed publications addressing PTSD, sexual dysfunction, and transphobia in healthcare. Dr. Gareayaghi is multilingual, speaks advanced English and elementary French, and is a passionate advocate for volunteerism, animal welfare, and nature conservation, integrating her holistic outlook into her psychiatric practice.

Profile

🎓 Education

Dr. Aila Gareayaghi began her academic journey with a High School Diploma from Matthew McNair Secondary School in Vancouver, Canada (2012). She earned her Doctor of Medicine (M.D.) from Bezmialem Vakıf University, Istanbul, Türkiye (2012-2018), where she built a strong foundation in medical sciences. During her medical training, she completed a prestigious clerkship in Gastroenterology at Johns Hopkins University, USA (2018), gaining international exposure to advanced clinical practices. Pursuing her passion for mental health, she specialized in Psychiatry at Kocaeli University, Türkiye (2020-2024). Under the mentorship of Prof. Dr. Elif Tatlıdil, she completed her thesis on “Telepsychiatry Services During the February 6 Earthquakes and PTSD Prevalence Six Months Later.” Additionally, Dr. Gareayaghi continuously expanded her expertise through numerous certifications in psychotherapy, cognitive behavioral therapy, dynamic psychotherapy, EMDR, and traditional Chinese medicine, emphasizing her dedication to comprehensive psychiatric care.

🧪 Experience

Dr. Gareayaghi’s professional experience reflects a blend of clinical practice, teaching, and research. She currently serves as Lecturer and Psychiatrist at the Department of Psychiatry, Kocaeli University (2024–Present), where she actively treats patients, mentors students, and conducts impactful research. As Chair of the Kocaeli Branch of the Psychiatric Association of Türkiye, she plays a leadership role in advancing psychiatric practice and policy at the regional level. Her experience extends internationally, having completed a clinical clerkship in Gastroenterology at Johns Hopkins University, USA. Dr. Gareayaghi has presented her research extensively at national and international psychiatric congresses, covering topics from disaster psychiatry to psychosis and caregiver support. Her work demonstrates strong expertise in trauma therapy, online psychotherapy, and managing complex psychiatric conditions. She is also a prolific contributor to academic literature, authoring multiple peer-reviewed articles and book chapters addressing psychiatric emergencies and psychological trauma interventions.

🏅 Awards and Honors

Dr. Aila Gareayaghi has distinguished herself through numerous scientific contributions and recognitions. She has been invited as a speaker at prestigious forums such as the 59th National Psychiatry Congress and the Symposium on Disaster and Disaster Management. Her presentations on post-earthquake PTSD, antipsychotic-induced complications, and caregiver support have been recognized for their clinical relevance and academic rigor. Dr. Gareayaghi’s research, including peer-reviewed publications on telepsychiatry and transphobia in healthcare, reflects her innovative approach to contemporary psychiatric challenges. Although formal awards are not specified, her active involvement as Chair of the Kocaeli Branch of the Psychiatric Association of Türkiye and her multiple invited speaker roles demonstrate high professional regard and peer recognition. Moreover, her extensive certifications in psychotherapy modalities underscore her commitment to lifelong learning and excellence in patient care. Her dedication to volunteer work and animal welfare also highlight her compassionate engagement beyond academia.

🔬 Research Focus

Dr. Gareayaghi’s research focuses primarily on trauma-informed care, disaster psychiatry, and telepsychiatry, with a special emphasis on the mental health impact of natural disasters. Her thesis work examined the prevalence of PTSD following Türkiye’s 2023 earthquakes and the effectiveness of telepsychiatry services during disaster recovery. Additionally, her research explores societal and clinical aspects of sexual dysfunction, major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. She has published studies addressing transphobia in healthcare, antipsychotic-induced complications, and innovative therapeutic interventions such as EMDR. Dr. Gareayaghi integrates various therapeutic modalities, including dynamic psychotherapy, cognitive behavioral therapy, and psychodynamic psychotherapy, into both her clinical practice and research. Her multidisciplinary approach bridges clinical psychiatry, public health, and social psychology, contributing valuable insights into the management of psychiatric emergencies and the psychological aftermath of crises. Her ongoing work continues to address evolving mental health challenges in both individual and systemic contexts.

Conclusion

Dr. Aila Gareayaghi exemplifies a dynamic psychiatrist integrating clinical excellence, cutting-edge research, and compassionate care, with a focus on trauma therapy, disaster psychiatry, telepsychiatry, and comprehensive psychiatric education.

Publications
  • Ruh Sağlığında Kriz

    ÖGDA GAREAYAGHİ, UDH YILMAZ, A POLAT
    PSİKİYATRİK ACİLLER
  • A MEDICAL STUDENT’S PERSPECTIVE ON ANIMAL EXPERIMENTATION.
    A Gareayaghi
    The Turkish Journal of Gastroenterology: the Official Journal of Turkish …
  • Predictors of Transphobia and Attitudes Toward Transgender Individuals Among Nurses in Türkiye: A Cross-Sectional Study

    Healthcare
    2025-06-19 | Journal article
    CONTRIBUTORS: Ezgi Şişman; Mehtap Güngör; Aila Gareayaghi; Hanife Yılmaz; Aslıhan Polat
  • Post-Earthquake PTSD and the Role of Telepsychiatry: A Six-Month Follow-Up Study After the 2023 Kahramanmaraş Earthquakes

    Medicina
    2025-06-17 | Journal article
    CONTRIBUTORS: Aila Gareayaghi; Elif Tatlıdil; Ezgi Şişman; Aslıhan Polat
  • Experiences with Brexpiprazole in the Management of Agitation Due to Dementia in a University Clinic: A Case Series

    Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
    2025-03-21 | Journal article
    CONTRIBUTORS: Aila Gareayaghi; Ezgi Şişman; Mert Türksoy; Aslıhan Özlem Polat Işık

Dyandevi mathure | Nanoformulation for Alzheimer’s disease | Best Researcher Award

Dr. Dyandevi mathure | Nanoformulation for Alzheimer’s disease | Best Researcher Award

Dr. Dyandevi Mewalal Mathure, Assistant Professor at Bharati Vidyapeeth, Poona College of Pharmacy, Pune, is a distinguished academician with over 15 years of experience in pharmaceutical sciences. Holding a Ph.D. in Pharmaceutical Sciences, she has significantly contributed to teaching, research, and innovation. Dr. Mathure has authored three notable books, published 18 research articles in reputed journals, and holds five published patents. Her research primarily focuses on nanoformulations for Alzheimer’s disease, wound healing, and topical formulations for skin diseases. She has successfully completed government-funded research projects and is actively engaged in industry consultancy work. Collaborating with institutions like the University of Petroleum and Energy Studies, Dehradun, Dr. Mathure continues to push the frontiers of pharmaceutical research. Her dedication is reflected in multiple accolades, including best paper presentation awards at international conferences. Committed to translational pharmaceutical advancements, she remains a passionate contributor to academia and industry alike.

Profile

🎓 Education

Dr. Dyandevi Mewalal Mathure earned her Ph.D. in Pharmaceutical Sciences, building a robust foundation in pharmaceutical research and innovation. Her academic journey has been characterized by a strong emphasis on novel drug delivery systems, formulation development, and translational research. She has engaged in continuous professional development, authoring several key texts in Industrial Pharmacy and Modern Dispensing Practices, which are widely used in academic curricula. Her educational background not only reflects depth in pharmaceutical sciences but also showcases her commitment to knowledge dissemination through teaching and publication. Her advanced training and research expertise in nanoformulations, brain-targeted drug delivery, and topical therapeutic systems underscore her position as a subject matter expert. Dr. Mathure’s education has enabled her to bridge theory and practice, equipping her with the skills to lead significant research projects, collaborate with industry partners, and mentor future pharmacists and researchers.

🧪 Experience

With over 15 years of academic and research experience, Dr. Dyandevi Mewalal Mathure has built a distinguished career as an Assistant Professor at Bharati Vidyapeeth, Poona College of Pharmacy, Pune. Her professional journey encompasses extensive teaching, research supervision, and collaborative research projects. She has published 18 papers in esteemed SCI and Scopus-indexed journals, authored three textbooks, and successfully filed five patents. Dr. Mathure has completed one funded research project and is currently engaged in an ongoing industry consultancy project, demonstrating her ability to translate academic research into practical applications. Her collaborations with institutions like the University of Petroleum and Energy Studies highlight her commitment to multidisciplinary research. Additionally, her expertise in nanoformulations for Alzheimer’s disease, wound healing, and skin disorders reflects her diverse research interests. Through her dedicated mentorship and active participation in international conferences, she continues to inspire and guide students, contributing significantly to the advancement of pharmaceutical sciences.

🏅 Awards and Honors

Dr. Dyandevi Mewalal Mathure has been recognized for her outstanding research contributions through multiple awards and honors. Notably, she received the Best Paper Presentation Award at the international e-Conference on “Expanding Frontier of Pharmaceutical Research Towards Global Exigency,” organized by Karpagam College of Pharmacy in association with the Indian Pharmaceutical Association, Coimbatore Branch. Her consistent scholarly excellence is reflected in her extensive publication record and successful patent filings. Dr. Mathure’s innovative work has garnered appreciation from both academia and industry, enhancing her reputation as a leader in pharmaceutical research. In addition to her academic accolades, her active involvement in consultancy projects further validates the real-world impact of her research. Her sustained commitment to innovation, teaching excellence, and translational research has made her a strong contender for the Best Research Award, recognizing her as a role model in the field of pharmaceutical sciences.

🔬 Research Focus

Dr. Dyandevi Mewalal Mathure’s research focuses on developing advanced nanoformulations aimed at treating Alzheimer’s disease, promoting wound healing, and addressing various dermatological conditions through innovative topical formulations. Her work emphasizes the design and optimization of novel drug delivery systems that enhance therapeutic efficacy and patient compliance. Through her publications, patents, and consultancy projects, Dr. Mathure has contributed to the advancement of brain-targeted drug delivery, an area critical for managing neurodegenerative diseases. Her translational research bridges laboratory discoveries with clinical and industrial applications, offering practical solutions to complex medical challenges. Collaborations with reputed institutions like UPES Dehradun further demonstrate her commitment to multidisciplinary and applied pharmaceutical research. With a citation index of 6, she maintains an active presence in scientific discourse, continuously advancing the boundaries of pharmaceutical sciences. Her work exemplifies innovation-driven research with tangible societal impact.

Conclusion

Dr. Dyandevi Mewalal Mathure’s distinguished academic career, marked by impactful research in nanoformulations, drug delivery, numerous publications, patents, and active industry collaborations, demonstrates her unwavering commitment to advancing pharmaceutical sciences and improving patient care through innovation and translational research.

Publications

Jolanta Dorszewska | Neurobiology | Women Researcher Award

Dr. Jolanta Dorszewska | Neurobiology | Women Researcher Award

Professor Jolanta Dorszewska is a globally recognized neuroscientist and pharmacologist based at Poznan University of Medical Sciences, Poland 🧠🇵🇱. She leads the Laboratory of Neurobiology, exploring the molecular and genetic basis of neurodegenerative diseases 🧬. With over 35 years of academic experience, her work spans neurochemistry, clinical neurology, and genetic research in Alzheimer’s and Parkinson’s disease 🧪. A prolific author, she has contributed to 80+ research papers, 50+ reviews, and 30+ book chapters 📚. She serves on editorial boards of top neuroscience journals and holds leadership roles in national and international neurological societies 🌍.

Profile

Education 🎓

Prof. Dorszewska earned her M.Sc. in Pharmacy with distinction from Poznan University of Medical Sciences in 1987 🏅. She completed board certifications in Pharmaceutical Analytics (1990 & 1997) and received her Ph.D. in 1996 🧪. In 2004, she qualified as an Associate Professor and achieved full Professorship in 2016 🎓. Her academic growth includes training in medical genetics from 2012 to 2020 🧬. Her education reflects an evolving blend of pharmacy, neurobiology, and genetics, forming the foundation of her current research excellence 💡.

Experience 👨‍🏫

Prof. Dorszewska began as an Assistant in the Dept. of Pharmacy (1987-88), then in Clinical Neurochemistry (1988-96) at PUMS 👩‍🔬. She was a Research Scientist in New York (1999–2000) 🗽 and has led the Laboratory of Neurobiology since 2004 🧠. She became Full Professor in 2022 🏛️. She also lectured at the National High Medical School in Pila (2012–2018) 📖. Her career blends hands-on research, global collaboration, and dedicated academic leadership 📚. She continues to mentor, publish, and drive innovations in neurology and neurochemistry 🚀

Awards & Recognitions 🏅

Awards and Honors:
Prof. Dorszewska is a Local Honorary Member of the 12th World Congress on Controversies in Neurology (2018) 🌐. She has served as Guest Editor for 6 prestigious theme issues and holds editorial roles in top-tier journals like Frontiers in Molecular Neuroscience and Current Alzheimer Research 📘. A section and associate editor for journals across the USA, UK, and Poland 🌍, she’s a key figure in scientific publishing 🖋️. She’s affiliated with the Polish Academy of Sciences and international neurological societies and has co-edited 5 books 📚.

Research Interests 🔬

Research Focus:
Her research spans lipid metabolism in hypoxia 🧫, cerebral sterols 🧠, neurotransmitters (serotonin, dopamine) 🧪, apoptosis in aging and disease (Alzheimer’s, Parkinson’s) 💔, and gene polymorphisms (MTHFR, MAO-B, PARK) 🧬. She investigates homocysteine metabolism, catecholamine pathways, and molecular changes in neurodegeneration 🧠. Since 2009, she’s focused on genetic mutations (PARK, APOE), biomarkers (ASN, microRNAs), and migraine genetics ⚙️. She uses advanced techniques like HPLC, PCR, ELISA, and immunohistochemistry 🔍. Her interdisciplinary work integrates neurobiology, pharmacogenomics, and molecular neuroscience in tackling brain diseases 🚀.

Publications 
  • Genetic variants of ZNF746 and the level of plasma Parkin, PINK1, and ZNF746 proteins in patients with Parkinson’s disease

    IBRO Neuroscience Reports
    2025-06 | Journal article
    CONTRIBUTORS: Jolanta Dorszewska; Jolanta Florczak-Wyspiańska; Bartosz Słowikowski; Wojciech Owecki; Oliwia Szymanowicz; Ulyana Goutor; Mateusz Dezor; Paweł P. Jagodziński; Wojciech Kozubski
  • Kinesiotherapeutic Possibilities and Molecular Parameters in Multiple Sclerosis

    Sclerosis
    2025-04-03 | Journal article
    CONTRIBUTORS: Katarzyna Wiszniewska; Małgorzata Wilk; Małgorzata Wiszniewska; Joanna Poszwa; Oliwia Szymanowicz; Wojciech Kozubski; Jolanta Dorszewsk
  • Unraveling the Role of Proteinopathies in Parasitic Infections

    Biomedicines
    2025-03-03 | Journal article
    CONTRIBUTORS: Mikołaj Hurła; Damian Pikor; Natalia Banaszek-Hurła; Alicja Drelichowska; Jolanta Dorszewska; Wojciech Kozubski; Elżbieta Kacprzak; Małgorzata Paul
  • Expression of Neuronal Nicotinic Acetylcholine Receptor and Early Oxidative DNA Damage in Aging Rat Brain—The Effects of Memantine

    International Journal of Molecular Sciences
    2025-02-14 | Journal article
    CONTRIBUTORS: Małgorzata Anna Lewandowska; Agata Różycka; Teresa Grzelak; Bartosz Kempisty; Paweł Piotr Jagodziński; Margarita Lianeri; Jolanta Dorszewska

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication

said Pournaghash-tehrani | Neuroscience | Best Faculty Award

Dr. said Pournaghash-tehrani | Neuroscience | Best Faculty Award

 

Profile

  • Googlescholar
  • Researchgate

Education

Said Pournaghash-Tehrani earned his Doctor of Philosophy in Psychology in 1993 from The American University in Washington, D.C., where he also completed his Master of Arts in Psychology in 1990. He holds a Bachelor of Science in Distributive Science from the same institution, which he obtained in 1986. Fluent in English and German, he also has familiarity with French. He can be reached via email at spournaghash@yahoo.com or by telephone at 011-98-09122074388.

Work experience
  • Said Pournaghash-Tehrani has extensive academic and research experience in psychology. He served as a Research Associate in 2001 at the Department of Pharmacology and Experimental Therapeutics, Loyola University’s Stritch School of Medicine in Chicago, Illinois. In 2002, he took a sabbatical as a researcher at the Department of Psychology, Carleton University in Ottawa, Canada, focusing on cross-cultural studies related to Iranian attitudes towards the West. Since 2002, he has been an Assistant Professor in the Department of Psychology at Tehran University, having previously held the same position at Azzahra University in Tehran from 1996 to 2001. Additionally, he was a member of the Scientific Council on Energy and Economic Studies at the Institute for International and Political Studies (IPIS) from 1998 to 2000, where he also worked as a political researcher. His early academic career included serving as a Teaching and Research Assistant at The American University’s Department of Psychology from 1987 to 1990, where he contributed to courses such as Introduction to Psychology, Neuroscience Seminar, Psychopharmacology, Neuropsychology, Biological Basis of Behavior, and Learning and Behavior.

Books

Fundamentals of Clinical Psychopharmacology, (2007); Samt Publications
-Drugs and Behavior, (2004); Samt Publications.
-Physiological Psychology, Tehran University Publication.
-Intimacy; Alzahra University Publication.
-Theories of Addiction, Alzahra University Publication.

Conference Presentations

Said Pournaghash-Tehrani has contributed extensively to neuroscience and psychology research, presenting his findings at prestigious conferences such as the Society for Neuroscience and the Eastern Psychological Association. His work has focused on drug discrimination learning, conditioned taste aversion, and the effects of opioids and their antagonists. In 1987, he co-authored studies assessing the discriminative stimulus properties of naloxone and the failure of cholecystokinin to counteract morphine sulfate’s effects. His later research explored the antagonism of morphine stimuli, the role of buprenorphine in opiate-naive and dependent animals, and the impact of RO15-4513 on ethanol-induced taste aversion. He has collaborated with notable researchers, including A.L. Riley, contributing to investigations on diazepam exposure and behavioral toxicology. His presentations in New Orleans, Washington, D.C., Boston, and other major research venues highlight his significant role in advancing psychopharmacology and behavioral neuroscience.

Publication

Marcelo Luis Berthier | Neuroscience| Best Researcher Award

Prof. Marcelo Luis Berthier | Neuroscience| Best Researcher Award

 

Unversidad de Málaga, Spain

Profile

Education

Marcelo Luis Berthier obtained his degree in Medicine (1972-1976) and completed residency training in Neurosurgery (1977-1980), later specializing in Neurology (1980). He served as a staff neurologist at the Institute of Neurological Research, FLENI, Buenos Aires, Argentina (1980-1989), before becoming a research fellow in the Department of Neurology at Clinic Hospital of Barcelona, Spain (1989-1990). From 1991 to 2000, he was a staff neurologist and physician in charge of the Behavioural Neurology Unit at the Clinic University Hospital of Malaga. He earned a PhD in Neuroscience (cum laude) from the University of Malaga and coordinated the Group of Behavioural Neurology and Dementia of the Spanish Neurological Society (2004-2006). In 2004, he founded and directed the Unit of Cognitive Neurology and Aphasia at the Centro de Investigaciones Médico-Sanitarias, University of Malaga, leading it until 2023. Additionally, he served as the director of the Consolidated Research Group on Cognitive Neuroscience: Aphasia and Related Disorders (UNCA, C-12) at the Instituto de Investigación Biomédica de Málaga (IBIMA – Plataforma BIONAND).

Work experience

Dr. Marcelo L. Berthier Torres has led and contributed to several groundbreaking research projects in cognitive neurology and aphasia. As a co-investigator, he participated in the Telerehabilitation in Aphasia project (2021-2023), which evaluated the effectiveness of telerehabilitation compared to face-to-face therapy and identified predictive biomarkers of response, funded by the Junta de Andalucía. He also served as the principal investigator for a study on the efficacy of combined treatment with donepezil, intensive rehabilitation, and transcranial direct current stimulation in chronic post-stroke aphasia (2016-2019), funded by the Instituto de Salud Carlos III. Additionally, he has contributed to the Proyectos de Generación de Conocimiento “Frontera”, an initiative under the FEDER Andalucía 2014-2020 program, which investigates brain biomarkers for individualized treatment approaches in chronic post-stroke aphasia

Areas of Research

Dr. Marcelo L. Berthier Torres has made significant contributions to the treatment of post-stroke aphasia and speech-language disorders. He conducted the first open-label and randomized, placebo-controlled, double-blind trials investigating the use of cognitive-enhancing drugs (donepezil and memantine) alone and in combination with standard aphasia therapy or intensive language-action therapy (ILAT) in chronic post-stroke aphasia. His pioneering studies stimulated international research on aphasia pharmacotherapy, leading to clinical translation. Today, donepezil and memantine, alone or combined with therapy, are widely used off-label for post-stroke aphasia and language disturbances associated with neurodegenerative disorders like Alzheimer’s disease and primary progressive aphasia.

Publication

  • Revisiting the boundaries of different altered accents profiles

    Cortex
    2025-03 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Ignacio Moreno-Torres; Jo Verhoeven; Guadalupe Dávila
  • Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

    CNS Drugs
    2023-07 | Journal article
    CONTRIBUTORS: Guadalupe Dávila; María José Torres-Prioris; Diana López-Barroso; Marcelo L. Berthier
  • Pharmacotherapy for post-stroke aphasia: what are the options?

    Expert Opinion on Pharmacotherapy
    2023-07-24 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Guadalupe Dávila
  • Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia

    Brain Structure and Function
    2023-05-31 | Journal article
    CONTRIBUTORS: Diana López-Barroso; José Paredes-Pacheco; María José Torres-Prioris; Guadalupe Dávila; Marcelo L. Berthier
  • Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia

    Aphasiology
    2022-11-02 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Daniel Santana-Moreno; Álvaro Beltrán-Corbellini; Juan C. Criado-Álamo; Lisa Edelkraut; Diana López-Barroso; Guadalupe Dávila; María José Torres-Prioris

Wei Jiang | Cognitive and neuropathology | Women Researcher Award

 Dr. Wei Jiang | Cognitive and neuropathology | Women Researcher Award

Medical University of South Carolina , United States

Her academic focus includes microbiome, B cell/autoantibody interactions, and disease pathogenesis, with particular emphasis on HIV, addictive drugs, and systemic lupus erythematosus (SLE). She is involved in several clinical and translational research projects, including R01DA059854 (Jiang & Sheng), investigating the impacts of drug abuse on autoantibodies and immune reconstitution in HIV. She also works on CSRD Merit I01 CX002422, exploring B cell-mediated immunological failure in HIV-infected individuals on antiretroviral therapy. Additionally, she contributes to NIDA-funded studies, such as R01DA055523, examining the oral microbiome’s effect on cognition in HIV-infected cannabis users, and R01DA059538, investigating HIV persistence in cocaine users. Furthermore, she collaborates on a Translational Science Award project exploring the oral microbiome’s impact on cognition in Alzheimer’s disease.

 

 

Profile

Education:

She earned her M.S. in Epidemiology and Biostatistics from Case Western Reserve University, Medical School, Cleveland, USA, in 2012. Prior to that, she completed a Postdoctoral fellowship at Case Western Reserve University, Medical School, Cleveland, USA, in 2008. She holds an M.S. in Immunology from Capital Medical University, Beijing, China, which she completed in 2001. She also received her M.D. in Internal Medicine from Capital Medical University, Beijing, China, in 1997.

BRIEF RESEARCH INTEREST STATEMENT:

She has 8 years of clinical experience in infectious diseases and 22 years of translational research experience in disease immunopathogenesis. As a corresponding author, she has published 52 peer-reviewed articles on microbiome and disease immunopathogenesis in high-profile journals like Microbiome, Arthritis & Rheumatology, J Autoimmunity, and EbioMedicine, bringing her total number of peer-reviewed publications to 101. As a physician-scientist, she has served as Principal Investigator on five R01 grants from NIAID or NIDA, along with a VA clinical merit grant, focusing on microbiomes, drug abuse, autoimmunity, and HIV immunopathogenesis. Her research primarily focuses on two major areas. The first is understanding the role of B cell perturbation and autoantibodies in disease pathogenesis, particularly in HIV and SLE. In 2017, her team first determined that autoimmunity impacts antiretroviral therapy outcomes in HIV without inducing autoimmune disease. This concept was later corroborated in studies on COVID-19. Her team is currently developing monoclonal autoantibodies and inhibitors to prevent anti-CD4 autoantibody binding, aiming to improve CD4+ T cell recovery and reduce morbidity in HIV patients. The second area of focus is the role of microbiomes in disease pathogenesis, including HIV, SLE, and drug abuse. She has identified the impact of disease-associated pathobionts on immune perturbations and disease progression, with findings validated in animal models. Her microbiome research is supported by R01DA055523.

TRAINING, PROFESSIONAL APPOINTMENTS

She currently serves on the Appointment, Promotion & Tenure (APT) committee in the Department of Microbiology and Immunology at the Medical University of South Carolina, a position she has held since 2024. She was promoted to Full Professor with tenure in the Department of Microbiology and Immunology, Division of Infectious Diseases, Department of Medicine at the same institution in 2023. She has been a Faculty Senator for the College of Medicine and a Research Health Scientist at the Ralph H. Johnson VA Medical Center since 2022. Additionally, she is a member of the Translational Science Laboratory IAC (2020-2022) and the MUSC College’s Curriculum Committee (2019-Present). She has held various positions at MUSC, including Associate Professor (2018-2022) and Assistant Professor (2012-2018) in the Department of Microbiology and Immunology. Since 2018, she has been a member of the Hollings Cancer Center at MUSC and has served on the award committee for the Advancement, Recruitment, and Retention of Women in Science. Her academic career began as an Instructor (2008-2012) and Research Associate (2002-2008) at Case Western Reserve University School of Medicine in Cleveland, OH.

AWARDS

She received her Chinese Board of Internal Medicine certification in Infectious Diseases in July 1997 and was certified as an Attending Medical Doctor in Infectious Diseases in November 1999 (No: 10203C089758). In July 1997, she also earned a Teacher Qualification from the Educational Institute, National Educational Committee in China (No: 971100071069382). Her licensure is from Beijing, China.

She has received several awards throughout her career, including the Laboratory Travel Grant from the American Association of Immunologists (AAI) in 2019, the MUSC High Impact Research Publication Award in 2019, and multiple travel grants from AAI for various international immunology congresses. She was awarded the Early Career Faculty Travel Grant by AAI and ECI in 2018 and 2017, and received the Travel Award and HIV Section Chair recognition at the 2016 International Congress of Immunology. In 2015, she was honored with the MUSC Foundation Developing Scholar Award and an Early Career Faculty Travel Grant from AAI. Her earlier achievements include multiple Young Investigator Awards from the 13th and 15th Conferences on Retroviruses and Opportunistic Infections (2006, 2008) and the Keystone Meeting on HIV Pathogenesis (2006, 2008). Additionally, she was recognized as an Outstanding Student Leader for five consecutive years during her medical school years from 1986 to 1991.

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

She has held several key professional roles and memberships throughout her career. Since 2024, she has been serving as a mentor for the American Society for Microbiology (ASM) Future Leaders Mentorship Fellowship (FLMF) Program. She is a member of the Society on NeuroImmune Pharmacology 2024 committee and has been a Treasurer Elect for the Association of Chinese Virologists in America from 2022 to 2024. She has been a member of the American Society for Microbiology (ASM) since 2021 and the Infectious Diseases Society of America (IDSA) since 2020. She has also been serving on the Editorial Board of the Journal of Neuroimmune Pharmacology since 2019 and is a member of the Society on NeuroImmune Pharmacology. Additionally, she has been part of the Society of Chinese Bioscientists in America (SCBA) and the American College of Rheumatology since 2018. She has contributed as an award committee member for the Advancement, Recruitment, and Retention of Women in Science at the Medical University of South Carolina since 2017 and is an associate member of the Hollings Cancer Center at MUSC.

She is also an active member of the MUSC Oral Health Center, College of Dental Medicine, and the Medical University of South Carolina College of Graduate Studies. Her previous memberships include being part of the American Association of Immunologists from 2011 to 2021, the Center for AIDS Research from 2008 to 2012, and the AIDS Clinic Trial Group since 2008. Her certification in Chinese Board of Internal Medicine in Infectious Diseases dates back to 1997, along with her teacher qualification from the Educational Institute, National Educational Committee, China.

CURRENT RESEARCH PROJECTS

She is currently leading several impactful research projects. As the Principal Investigator (PI) on R01DA059854 (9/30/2024-5/31/2029), funded by NIDA with a total of $3,924,302, she is studying the impacts of drug abuse-mediated inflammatory perturbations on affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from ART in HIV. This project aims to understand the role of cocaine in autoimmunity and immune recovery in HIV patients. Her role in this project is as PI (25% effort).

She is also a multiPI on R01DA059538 (9/30/2023-7/31/2028), with a total of $1,724,585 from NIDA, investigating host gene isoforms contributing to HIV persistence in cocaine users. The study focuses on identifying gene isoforms associated with HIV infection in elite controllers and its implications for cocaine users. Her role is PI (25% effort).

In addition, she is the PI on I01CX002422 (3/1/2022-2/28/2026), funded by the VA Medical Center CSRD Merit with a total of $1,195,899. This project examines the mechanism of autoreactive B cell-mediated immunological failure in HIV-infected individuals on antiretroviral therapy despite virologic suppression. She is focused on understanding the molecular mechanisms of anti-CD4 IgG-producing B cells and the pathologic effects of anti-CD4 autoantibodies. Her role is PI with 62.5% effort.

Additionally, she is involved as multiPI on R01DA055523 (9/30/2022-7/31/2027), with a total funding of $1,731,992, where she is working alongside Fitting to investigate the effects of microbiome-related mechanisms on H

 Publication